Mesoblast Limited Email Format

Biotechnology ResearchVictoria, Australia51-200 Employees

Mesoblast Limited is a biotechnology company focused on developing allogeneic cellular medicines to treat serious inflammatory diseases with significant unmet medical needs. Its late-stage pipeline consists of off-the-shelf mesenchymal lineage cell products intended for four indications, including steroid-refractory acute graft-versus-host disease, ARDS related to COVID-19, advanced chronic heart failure, and chronic low back pain due to degenerative disc disease. The company emphasizes rigorous scientific investigation of well-characterized cell populations and relies on extensive preclinical work and controlled clinical trials overseen by independent safety review boards.

Based in Melbourne, Victoria, Australia, Mesoblast operates within the biotechnology research sector and aims for broad, globally available cell therapies. It maintains an extensive intellectual property portfolio of about 1,000 patents and applications protecting composition, manufacturing, and therapeutic uses of mesenchymal lineage cells, with protection extending through 2040. In April 2026, the company launched RYONCIL and pursued additional developments, including acquiring Mayo Clinic CAR-MSC IP and partnering with Parent Project Muscular Dystrophy to support trial recruitment.

Get verified Mesoblast Limited emails free

Company overview Employee directory